Juno Therapeutics Company Profile (NASDAQ:JUNO)

About Juno Therapeutics

Juno Therapeutics logoJuno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno's product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company's CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: JUNO
  • CUSIP:
Key Metrics:
  • Previous Close: $23.13
  • 50 Day Moving Average: $20.69
  • 200 Day Moving Average: $25.61
  • 52-Week Range: $17.52 - $49.72
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.19
  • P/E Growth: 0.00
  • Market Cap: $2.37B
  • Outstanding Shares: 102,614,000
  • Beta: 2.27
  • Net Margins: -445.86%
  • Return on Equity: -22.10%
  • Return on Assets: -17.49%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 6.35%
  • Quick Ratio: 6.35%
Additional Links:
Companies Related to Juno Therapeutics:

Analyst Ratings

Consensus Ratings for Juno Therapeutics (NASDAQ:JUNO) (?)
Ratings Breakdown: 7 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $38.43 (66.43% upside)

Analysts' Ratings History for Juno Therapeutics (NASDAQ:JUNO)
DateFirmActionRatingPrice TargetDetails
2/22/2017Wells Fargo & CompanyInitiated CoverageOutperform -> PositiveView Rating Details
2/1/2017WedbushInitiated CoverageNeutral$24.00View Rating Details
1/11/2017J P Morgan Chase & CoReiterated RatingHoldView Rating Details
12/6/2016FBR & CoSet Price TargetHold$30.00View Rating Details
12/6/2016Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformView Rating Details
12/5/2016Cowen and CompanyReiterated RatingBuy$51.00View Rating Details
12/5/2016Maxim GroupSet Price TargetBuy$34.00View Rating Details
11/28/2016Leerink SwannReiterated RatingOutperform$45.00 -> $34.00View Rating Details
11/25/2016SunTrust Banks, Inc.DowngradeBuy -> Hold$48.00 -> $25.00View Rating Details
11/23/2016BTIG ResearchReiterated RatingNeutralView Rating Details
8/25/2016Standpoint ResearchInitiated CoverageBuy$47.00View Rating Details
7/6/2016Barclays PLCInitiated CoverageEqual Weight$48.00View Rating Details
4/8/2016Morgan StanleyBoost Price Target$48.00 -> $50.00View Rating Details
2/27/2016Deutsche Bank AGInitiated CoverageBuyView Rating Details
2/25/2016Citigroup Inc.Initiated CoverageBuy$45.00View Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$50.00 -> $41.00View Rating Details
2/17/2016GuggenheimUpgradeNeutral -> BuyView Rating Details
7/22/2015Northland SecuritiesInitiated CoverageOutperform$64.00View Rating Details
(Data available from 2/22/2015 forward)


Earnings History for Juno Therapeutics (NASDAQ:JUNO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016Q316($0.52)($0.57)$10.98 million$20.80 millionViewListenView Earnings Details
8/4/2016Q216($0.41)($0.64)$14.26 million$27.60 millionViewListenView Earnings Details
5/9/2016Q116($0.52)($0.78)$4.83 million$9.80 millionViewListenView Earnings Details
2/29/2016Q415($0.47)($0.53)$4.79 million$4.15 millionViewListenView Earnings Details
11/10/2015Q315($0.41)($0.53)$6.41 million$1.60 millionViewListenView Earnings Details
8/12/2015Q215($0.37)($0.35)$2.03 million$12.50 millionViewListenView Earnings Details
5/11/2015Q115($0.35)($0.30)ViewListenView Earnings Details
3/18/2015Q414($0.33)($1.61)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Juno Therapeutics (NASDAQ:JUNO)
Current Year EPS Consensus Estimate: $-2.60 EPS
Next Year EPS Consensus Estimate: $-2.82 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.67)($0.67)($0.67)
Q2 20161($0.47)($0.47)($0.47)
Q3 20162($0.65)($0.55)($0.60)
Q4 20162($0.72)($0.58)($0.65)
(Data provided by Zacks Investment Research)


Dividend History for Juno Therapeutics (NASDAQ:JUNO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Juno Therapeutics (NASDAQ:JUNO)
Insider Ownership Percentage: 15.26%
Institutional Ownership Percentage: 61.80%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2016Robert AzelbyEVPSell12,921$24.14$311,912.94View SEC Filing  
9/27/2016Hans Edgar BishopCEOSell44,000$33.00$1,452,000.00View SEC Filing  
9/21/2016Hans Edgar BishopCEOSell84,035$30.28$2,544,579.80View SEC Filing  
9/8/2016Hans Edgar BishopCEOSell23,042$30.06$692,642.52View SEC Filing  
6/24/2016Richard KlausnerDirectorSell12,000$40.71$488,520.00View SEC Filing  
6/17/2016Hyam LevitskyEVPSell12,418$42.77$531,117.86View SEC Filing  
6/10/2016Steve HarrCFOSell30,000$43.32$1,299,600.00View SEC Filing  
6/9/2016Hans Edgar BishopCEOSell90,750$46.42$4,212,615.00View SEC Filing  
5/19/2016Bernard J CassidyGeneral CounselSell3,116$39.03$121,617.48View SEC Filing  
5/18/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00View SEC Filing  
4/19/2016Bernard J CassidyGeneral CounselSell3,200$43.12$137,984.00View SEC Filing  
4/15/2016Richard KlausnerDirectorSell12,000$42.90$514,800.00View SEC Filing  
3/28/2016Anthony B EvninDirectorBuy8,000$36.58$292,640.00View SEC Filing  
3/22/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00View SEC Filing  
3/18/2016Bernard J CassidyGeneral CounselSell3,200$38.18$122,176.00View SEC Filing  
3/4/2016Steve HarrInsiderSell5,000$45.00$225,000.00View SEC Filing  
3/2/2016Richard KlausnerDirectorSell24,000$40.42$970,080.00View SEC Filing  
3/1/2016Douglas K BrattonMajor ShareholderSell8,600,000$39.00$335,400,000.00View SEC Filing  
3/1/2016Steve HarrInsiderSell30,000$37.58$1,127,400.00View SEC Filing  
2/19/2016Bernard J. CassidyGeneral CounselSell3,200$34.50$110,400.00View SEC Filing  
1/19/2016Bernard J. CassidyGeneral CounselSell3,200$33.55$107,360.00View SEC Filing  
12/18/2015Bernard J. CassidyGeneral CounselSell3,200$45.39$145,248.00View SEC Filing  
12/10/2015Steve HarrinsiderSell35,000$46.43$1,625,050.00View SEC Filing  
11/19/2015Bernard J. CassidyGeneral CounselSell3,200$52.97$169,504.00View SEC Filing  
11/13/2015Richard KlausnerDirectorSell12,000$49.51$594,120.00View SEC Filing  
10/19/2015Bernard J. CassidyGeneral CounselSell3,200$49.85$159,520.00View SEC Filing  
10/15/2015Richard KlausnerDirectorSell8,000$50.00$400,000.00View SEC Filing  
10/12/2015Richard KlausnerDirectorSell16,000$50.00$800,000.00View SEC Filing  
9/18/2015Bernard J. CassidyGeneral CounselSell11,850$42.50$503,625.00View SEC Filing  
8/19/2015Bernard J. CassidyGeneral CounselSell11,850$40.15$475,777.50View SEC Filing  
7/17/2015Bernard J CassidyGeneral CounselSell11,850$50.55$599,017.50View SEC Filing  
7/15/2015Richard KlausnerDirectorSell8,000$53.34$426,720.00View SEC Filing  
7/2/2015Douglas K BrattonMajor ShareholderSell40,000$54.75$2,190,000.00View SEC Filing  
6/26/2015Anthony B EvninDirectorSell583,333$48.11$28,064,150.63View SEC Filing  
6/24/2015Bernard J CassidyGeneral CounselSell11,850$51.34$608,379.00View SEC Filing  
6/24/2015Douglas K BrattonMajor ShareholderSell270,000$51.13$13,805,100.00View SEC Filing  
6/23/2015Richard KlausnerDirectorSell8,000$52.29$418,320.00View SEC Filing  
6/18/2015Anthony B EvninDirectorSell583,333$52.88$30,846,649.04View SEC Filing  
12/23/2014Douglas K BrattonMajor ShareholderBuy625,000$24.00$15,000,000.00View SEC Filing  
12/23/2014Hal BarronDirectorBuy100,000$24.00$2,400,000.00View SEC Filing  
12/19/2014Douglas K BrattonMajor ShareholderBuy625,000$25.00$15,625,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Juno Therapeutics (NASDAQ:JUNO)
News IconBuy or Sell? Average Brokerage Ratings on Juno Therapeutics, Inc. (JUNO), Terex Corporation (TEX) - StockNewsJournal (NASDAQ:JUNO)
stocknewsjournal.com - February 20 at 5:33 PM
News IconJuno Therapeutics, Inc. (JUNO): The Technicals As Seen Today - NY Stock News (NASDAQ:JUNO)
nystocknews.com - February 18 at 5:27 PM
News IconWhy Analysts put forward these two stocks: TEGNA Inc. (TGNA ... - The USA Commerce (NASDAQ:JUNO)
theusacommerce.com - February 18 at 5:27 PM
sbwire.com logoNon-Small Cell Lung Cancer - Pipeline Review, H2 2016 - New Market Report (NASDAQ:JUNO)
www.sbwire.com - February 17 at 1:01 PM
gurufocus.com logoBb Biotech Ag Buys Myovant Sciences, Macrogenics, Juno Therapeutics, Sells Cempra, PTC Therapeutics - GuruFocus.com (NASDAQ:JUNO)
www.gurufocus.com - February 16 at 5:46 PM
News IconAre Analysts Optimistic About Where Juno Therapeutics, Inc. (NASDAQ:JUNO) is Heading? - Winfield Review (NASDAQ:JUNO)
winfieldreview.com - February 15 at 5:37 AM
streetinsider.com logoForm SC 13G/A Juno Therapeutics, Inc. Filed by: FMR LLC (NASDAQ:JUNO)
www.streetinsider.com - February 15 at 12:35 AM
News IconTechnicals in Focus for Juno Therapeutics, Inc. (JUNO) - The USA Commerce (NASDAQ:JUNO)
www.theusacommerce.com - February 14 at 7:33 PM
streetinsider.com logoForm SC 13G/A Juno Therapeutics, Inc. Filed by: FMR LLC - StreetInsider.com (NASDAQ:JUNO)
www.streetinsider.com - February 14 at 7:33 PM
News IconToday Analysts Focus on Juno Therapeutics, Inc. (JUNO), Omega Healthcare Investors, Inc. (OHI) - StockNewsJournal (NASDAQ:JUNO)
stocknewsjournal.com - February 14 at 7:33 PM
News IconAverage Brokerage Rating Of Juno Therapeutics, Inc. (JUNO), Toll Brothers, Inc. (TOL) - The USA Commerce (NASDAQ:JUNO)
theusacommerce.com - February 13 at 7:09 PM
News IconEarnings Clues on Juno Therapeutics, Inc. (JUNO), Leucadia National Corporation (LUK) Analyst's Predictions - StockNewsJournal (NASDAQ:JUNO)
stocknewsjournal.com - February 12 at 10:58 PM
reuters.com logoBRIEF-Vanguard Group reports 5.52 pct passive stake in Juno Therapeutics as of Dec. 31, 2016 - Reuters (NASDAQ:JUNO)
www.reuters.com - February 12 at 10:58 PM
News IconJuno Therapeutics, Inc. (NASDAQ:JUNO) Projected EPS At $-0.63 - Stock Observer (NASDAQ:JUNO)
www.thestockobserver.com - February 12 at 10:58 PM
News IconMabVax Therapeutics to Present at the BIO CEO & Investor Conference (NASDAQ:JUNO)
www.bio-medicine.org - February 10 at 6:55 PM
News IconGalectin Therapeutics Inc. (GALT) Receives Market Perform Rating from FBR & Co (NASDAQ:JUNO)
mlbinjurynews.com - February 10 at 6:55 PM
News IconAnalytical Guide for Juno Therapeutics, Inc. (JUNO), Kansas City Southern (KSU) Stakeholders - The USA Commerce (NASDAQ:JUNO)
www.theusacommerce.com - February 9 at 7:04 PM
businesswire.com logoJuno Therapeutics to Present at the Leerink Partners 6 - Business Wire (press release) (NASDAQ:JUNO)
www.businesswire.com - February 9 at 7:04 PM
fool.com logoIs This Why Juno Therapeutics, Inc. Stock Rose 13% in January? - Motley Fool (NASDAQ:JUNO)
www.fool.com - February 9 at 7:04 PM
wsj.com logo[$$] Venrock Refuels, and Goes Back on the Hunt (NASDAQ:JUNO)
www.wsj.com - February 9 at 7:04 PM
finance.yahoo.com logoJuno Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:JUNO)
finance.yahoo.com - February 8 at 6:51 PM
News IconGlobal CAR T Cell Therapy Market to Reach US$ 8.5 Billion by 2028 (NASDAQ:JUNO)
www.abnewswire.com - February 7 at 7:26 PM
fool.com logoIs This Why Juno Therapeutics, Inc. Stock Rose 13% in January? (NASDAQ:JUNO)
www.fool.com - February 7 at 12:43 PM
News IconJuno Therapeutics Inc (JUNO) is Initiated by Wedbush to "Neutral" - Highland Mirror (NASDAQ:JUNO)
www.highlandmirror.com - February 4 at 6:08 PM
finance.yahoo.com logoCoverage initiated on Juno Therapeutics by Wedbush (NASDAQ:JUNO)
finance.yahoo.com - February 2 at 6:48 PM
fool.com logoHere's Why Stemline Therapeutics Stock Fell 36.9% This Morning (NASDAQ:JUNO)
www.fool.com - February 2 at 6:48 PM
thestreet.com logoSide Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money (NASDAQ:JUNO)
www.thestreet.com - February 2 at 6:48 PM
capitalcube.com logoJuno Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JUNO-US : February 1, 2017 (NASDAQ:JUNO)
www.capitalcube.com - February 1 at 6:52 PM
News IconMy Watchlist for Wednesday, February 01 (NASDAQ:JUNO)
ac-investor.blogspot.com - January 31 at 6:55 PM
News IconNovartis signals ambitions for cancer treatments (NASDAQ:JUNO)
www.thegazette.com - January 30 at 6:48 PM
bizjournals.com logoJuno Therapeutics hires biotech vet in executive team expansion (NASDAQ:JUNO)
www.bizjournals.com - January 30 at 10:29 AM
News IconTrading Circle: Narrowing in on Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) - The Tribune (NASDAQ:JUNO)
lakecitytribune.com - January 29 at 11:26 PM
News IconJuno Therapeutics, Inc. (NASDAQ:JUNO) Projected EPS At $-0.67 - Stock Observer (NASDAQ:JUNO)
www.thestockobserver.com - January 29 at 11:25 PM
News IconStock Volume Ratcheting Up Mid-Session For Abbott Laboratories (NYSE:ABT) (NASDAQ:JUNO)
prensariotiretail.com - January 28 at 11:15 PM
businesswire.com logoJuno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations - Business Wire (press release) (NASDAQ:JUNO)
www.businesswire.com - January 28 at 6:14 PM
reuters.com logoBRIEF-Juno Therapeutics appoints Corsee Sanders as head of development operations (NASDAQ:JUNO)
www.reuters.com - January 27 at 8:12 PM
streetinsider.com logoJuno Therapeutics (JUNO) Names Corsee D. Sanders as EVP and Head of Development Operations (NASDAQ:JUNO)
www.streetinsider.com - January 27 at 8:12 PM
finance.yahoo.com logoJuno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations (NASDAQ:JUNO)
finance.yahoo.com - January 27 at 8:12 PM
News IconBlock Buying in Juno Therapeutics, Inc. (NASDAQ:JUNO) on Price Weakness - Highland Mirror (NASDAQ:JUNO)
www.highlandmirror.com - January 25 at 7:30 PM
bizjournals.com logoConstruction starts soon on $300M downtown Seattle Children's research facility (NASDAQ:JUNO)
www.bizjournals.com - January 20 at 9:25 PM
News IconCould immunotherapy cure HIV? $2.6M grant will help Fred Hutch researcher find out (NASDAQ:JUNO)
www.geekwire.com - January 20 at 4:17 PM
News IconNoteworthy Friday Option Activity: JUNO, SHLD, LJPC (NASDAQ:JUNO)
www.stockoptionschannel.com - January 20 at 4:17 PM
News IconTCR & CAR Engineered T-Cell And NK Cell Therapeutics 2016 – Research Study: MarketResearchReports.Biz (NASDAQ:JUNO)
www.medgadget.com - January 19 at 7:53 PM
News IconJuno Therapeutics (JUNO) Stock: Spiking On Takeover Chatter (NASDAQ:JUNO)
cnafinance.com - January 19 at 7:53 PM
nasdaq.com logoCommit To Buy Juno Therapeutics At $15, Earn 17.3% Using Options (NASDAQ:JUNO)
www.nasdaq.com - January 19 at 7:53 PM
News IconWhy Jay Bradner thinks Novartis can recharge drug discovery - BioPharma Dive (NASDAQ:JUNO)
www.biopharmadive.com - January 19 at 4:40 AM
News IconMy Watchlist for Thursday, January 19 (NASDAQ:JUNO)
ac-investor.blogspot.com - January 18 at 6:36 PM
News IconJuno Therapeutics, Inc. (NASDAQ:JUNO) Projected to Achieve EPS ... - Stock Observer (NASDAQ:JUNO)
www.thestockobserver.com - January 16 at 8:38 AM
nasdaq.com logoWhy Juno Therapeutics Crashed 57.1% in 2016 and What's Next - Nasdaq (NASDAQ:JUNO)
www.nasdaq.com - January 14 at 6:10 PM
fool.com logoWhy Juno Therapeutics Crashed 57.1% in 2016 and What's Next (NASDAQ:JUNO)
www.fool.com - January 13 at 7:22 PM


What is Juno Therapeutics' stock symbol?

Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."

Where is Juno Therapeutics' stock going? Where will Juno Therapeutics' stock price be in 2017?

14 analysts have issued 12-month price targets for Juno Therapeutics' shares. Their forecasts range from $23.00 to $52.00. On average, they expect Juno Therapeutics' stock price to reach $38.43 in the next year.

When will Juno Therapeutics announce their earnings?

Juno Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about Juno Therapeutics stock?

Here are some recent quotes from research analysts about Juno Therapeutics stock:

  • Wedbush analysts commented, "We see significant value in JUNO's leading array of engineered T-cell technologies that we believe could allow for a differentiated strategy in B-cell malignancies, despite being behind the competition in the race to market. However, competition from other CAR-T products is likely to limit shareholder upside in the near term." (2/1/2017)
  • According to Zacks Investment Research, "Juno suffered a huge setback in Jul 2016 with the FDA placing a clinical hold on a phase II study on JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia. While the hold was lifted a week later and the study resumed under a revised protocol, the company voluntarily placed the study on hold in Nov 2016, and is presently working with the FDA and a Safety Monitoring Board to determine future steps. Moreover, Juno’s shares underperformed the Medical-Biomed/Genetics industry significantly in the past one year. Estimates have been going down lately ahead of the company’s Q4 earnings release. The company has mixed record of earnings surprises in recent quarters. However, Juno continues to progress with its other pipeline candidates and continues to pursue acquisitions and licensing agreements to boost its pipeline." (1/10/2017)

  • Cowen and Company analysts commented, "At ASH on Monday and JUNO’s investor event, we believe that data from JUNO’s NHL/." (12/5/2016)

  • Leerink Swann analysts commented, "We’re using a 12% discount rate which we think is appropriate as we use probability-weighted sales estimates for the products and believe the CELG (MP) collaboration, equity investment and ex-US opt-in to CD19 programs lower the risk profile relative to Juno’s peers. We assume the CAR-T market will be split among up to 5 competitors long-term, depending on the indication, including JUNO, KITE, NVS, CLLS, BLUE and others, pending further validation of respective products. Based on the complexity of the technology and manufacturing and the lack of regulatory path for generic versions of CAR-T products as a result of patient-specific manufacturing, we believe that CAR-T product sales are sustainable even after the loss of patent exclusivity." (11/28/2016)

Who owns Juno Therapeutics stock?

Juno Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (10.78%), State Street Corp (3.33%), FMR LLC (1.87%), Temasek Holdings Private Ltd (0.89%), Arrowpoint Asset Management LLC (0.77%) and Brown Advisory Inc. (0.24%). Company insiders that own Juno Therapeutics stock include Anthony B Evnin, Bernard J Cassidy, Douglas K Bratton, Hans Edgar Bishop, Hyam Levitsky, Richard Klausner, Robert Azelby and Steve Harr.

Who sold Juno Therapeutics stock? Who is selling Juno Therapeutics stock?

Juno Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, AQR Capital Management LLC, Clarius Group LLC, Arrowpoint Asset Management LLC, Lumina Fund Management LLC and Baird Financial Group Inc.. Company insiders that have sold Juno Therapeutics stock in the last year include Bernard J Cassidy, Douglas K Bratton, Hans Edgar Bishop, Hyam Levitsky, Richard Klausner, Robert Azelby and Steve Harr.

Who bought Juno Therapeutics stock? Who is buying Juno Therapeutics stock?

Juno Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Brown Advisory Inc., Baillie Gifford & Co., ARK Investment Management LLC, Credit Agricole S A, Guggenheim Capital LLC, Tudor Investment Corp Et Al and Russell Investments Group Ltd..

How do I buy Juno Therapeutics stock?

Shares of Juno Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Juno Therapeutics stock cost?

One share of Juno Therapeutics stock can currently be purchased for approximately $23.09.

Juno Therapeutics (NASDAQ:JUNO) Chart for Wednesday, February, 22, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Earnings History Chart

Earnings by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Dividend History Chart

Dividend Payments by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Last Updated on 2/22/2017 by MarketBeat.com Staff